2Q24 PBPK QSP CPP REG Backlog $18.0 $17.0 $15.4 2Q22 2Q23 2Q24 17 Income Statement Summary - Q2 FY24 (in millions, except Diluted EPS) | --- | --- | --- | --- | --- | |----------------------------|-------|----------|-------|----------| | | 2Q24 | % of Rev | 2Q23 | % of Rev | | Revenue | $18.3 | 100% | $15.8 | 100% | | Revenue growth | 16% | | 6% | | | Gross profit | 13.2 | 72% | 13.1 | 83% | | R&D | 1.3 | 7% | 1.3 | 8% | | S&M | 1.9 | 11% | 1.7 | 11% | | G&A | 5.5 | 30% | 6.0 | 38% | | Total operating exp | ...

Financial Data and Key Metrics Changes - Total revenue increased by 16% to $18.3 million, with software revenue up 11% and services revenue up 27% [24][31] - Diluted earnings per share remained at $0.20, reflecting a decrease in diluted shares outstanding due to last year's share repurchase [32] - Total gross margin decreased to 72% from 83% year-over-year, with software gross margin at 88% versus 92% and services margin at 44% versus 66% [26][31] - Adjusted EBITDA increased to $7.1 million, maintaining 39% of revenue [33] Business Line Data and Key Metrics Changes - Software segment revenue increased by 11% in Q2 and 16% for the six-month period, with strong demand except for Asia [13][24] - Cheminformatics business unit saw a 14% revenue growth in Q2 and 10% year-to-date, driven by ADMET Predictor [14] - Clinical Pharmacology & Pharmacometrics (CPP) business unit delivered 38% revenue growth for the quarter and 21% year-to-date [19] - Quantitative Systems Pharmacology (QSP) revenue decreased by 6% for the quarter but increased by 77% year-to-date [20] Market Data and Key Metrics Changes - Biotech funding has been strong, particularly for companies with drug candidates in clinical trials, indicating a healthier market compared to the previous year [8][9] - Large pharmaceutical companies are experiencing varied funding based on their individual circumstances, with some companies like Pfizer announcing significant cutbacks [45][46] - The Asian market, particularly China, is lagging in spending, impacting overall growth [13][55] Company Strategy and Development Direction - The company is focusing on enhancing its AI capabilities in drug discovery and development, leveraging its access to accurate public and private data as a competitive edge [10][12] - A reorganization of business units was implemented to improve operational performance and profitability, with all services personnel moved into cost of revenue departments [25][26] - The company is committed to capital allocation strategies, seeking opportunities for strategic acquisitions and partnerships [37] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding demand for modeling and simulation software products as market conditions improve [9][39] - The company anticipates total revenue for fiscal 2024 to be between $66 million and $69 million, with year-over-year growth of 10% to 15% [40] - Management highlighted the importance of maintaining a strong balance sheet with no debt and a seasoned management team [41] Other Important Information - Total backlog at the end of Q2 was $18 million, indicating strong demand as the company enters the second half of the fiscal year [15][28] - The average revenue per customer increased to $95,000, with a customer renewal rate of 93% based on fees [27] Q&A Session Summary Question: How is the macroenvironment affecting large pharma funding? - Management noted that large pharma funding is influenced more by individual company circumstances rather than a general funding issue [45][46] Question: How quickly does biotech funding translate into bookings? - Management indicated that there is typically a lag of six to nine months before funding translates into purchasing decisions [48] Question: What drove the strong performance in ADMET Predictor? - The increase in customers and upsells was attributed to greater market acceptance and the technology's relevance amidst new AI solutions [50] Question: Can you discuss the sequential increase in GastroPlus revenue? - Management explained that the harmonization process completed last year has led to a different seasonal pattern, contributing to revenue growth [53][55] Question: How is Monolix performing in relation to clinical trial activity? - Monolix has been growing rapidly and is indirectly correlated with clinical trial activity, as demand for modeling and simulation increases with development programs [56][59] Question: What is the impact of the new corporate development effort? - The new effort aims to identify acquisition opportunities and potentially invest in companies that utilize the company's technology in drug development [62][64] Question: How does the company differentiate itself from newer AI ventures? - Management emphasized their long-standing experience and data access as key differentiators, maintaining a strong position in the market [66][72]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2023 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-32046 Simulations Plus, Inc. (Name of registrant as specified in its charter) California 95-4595609 (Stat ...

Simulations Plus, Inc. (NASDAQ:SLP) Q1 2024 Earnings Conference Call January 3, 2024 5:00 PM ET Company Participants Tamara Gonzalez - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer and Chief Operating Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group David Larsen - BTIG François Brisebois - Oppenheimer Operator Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2024 Financial Results Confe ...

2 CURRENT PERIOD | --- | --- | --- | --- | |------------------------------|-------------|-------------|---------| | | | | | | Prior Year Comparison (1Q23) | | | | | $12.0M | $0.06 | 25% | $15.8M | | Revenue | Diluted EPS | Adjusted | Backlog | | | | EBITDA as % | | | | | of Revenue | | GastroPlus® (Physiologically Based Pharmacokinetics) Q1 Revenue Growth General | --- | --- | |--------------------|-------------------------------------------------------------------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-32046 Simulations Plus, Inc. (Exact name of registrant as specified in its charter) California (State or othe ...

Simulations Plus, Inc. (NASDAQ:SLP) Q4 2023 Earnings Conference Call October 25, 2023 5:00 PM ET Company Participants Tamara Gonzales - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Matt Hewitt - Craig-Hallum David Larsen - BTIG David Windley - Jefferies Operator Greetings, and welcome to the Simulations Plus Fourth Quarter Fiscal 2023 Financial Results Conference Call. At ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended May 31, 2023 OR o Transmission Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-32046 Simulations Plus, Inc. (Name of registrant as specified in its charter) California 95-4595609 (State o ...

Simulations Plus, Inc. (NASDAQ:SLP) Q3 2023 Earnings Conference Call July 6, 2023 5:00 PM ET Company Participants John Wilfong - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum David Larsen - BTIG Yuan Zhi - B. Riley Francois Brisebois - Oppenheimer Operator Greetings, and welcome to the Simulations Plus Third Quarter Fiscal 2023 Financial Results Conference Call. At this time, al ...

Increases breadth and depth of QSP expertise and range of therapeutic applications 3Q22 Software Revenue Mix 60% to 65% FY23 Mix 11 SH ls + 92% 91% 90% ↑ 83% 82% 81% 9 66% 63% 63% 3Q21 3Q22 3Q23 - ●= Software ► Services ▼ Total 12 $5.3 $9.6 $5.6 $10.6 73Q21 3Q23 +9% +10% +5% Total Revenue Software Revenue Services Revenue 3Q23 Mix 35% 65% Software Services 3Q22 Mix 36% 64% Software Services 10 Revenue - YTD (in millions) Software Services | --- | --- | --- | --- | --- | |---------------|------------------|- ...